This product, named Exubera, is slated to be introduced into the United States market soon after the U.S. Food and Drug Administration approves it for use in adults with Type 1 or Type 2 diabetes.
Dr. Julio Rosenstock, trial investigator and director of the Dallas Diabetes & Endocrine Center said "There are a lot of physical barriers to injected insulin. This (Exubera) is a good tool to facilitate initiation of insulin treatment."
For those sufferings Type 2 diabetes, Exubera is permissible either alone or in combination with diabetes medication or longer-acting insulin. For type 1 diabetics, Exubera is advised to be combined with longer-acting insulin. This drug is not to be consumed by smokers, patients with lung problems and expecting women.